Effects of hepatitis B surface antigen (HBsAg) positivity of donors in HBsAg(+) renal transplant recipients: comparison of outcomes with HBsAg(+) and HBsAg(-) donors

Basit Öğe Kaydı
dc.contributor.authorYilmaz, V. T.
dc.contributor.authorAliosmanoglu, I.
dc.contributor.authorErbis, H.
dc.contributor.authorUlger, B. V.
dc.contributor.authorCetinkaya, R.
dc.contributor.authorSuleymanlar, G.
dc.contributor.authorKocak, H.
dc.date.accessioned2024-04-24T17:11:51Z
dc.date.available2024-04-24T17:11:51Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractAimThe aim of this study was to determine the effects of hepatitis B surface antigen (HBsAg) positivity of the donors on graft survival and liver complications in HBsAg(+) renal transplant recipients. Patients and methodA group of 55 patients who underwent renal transplantation (RTx) in our hospital between 2001 and 2012 were included in the study. Patients were divided into 2 groups. Group 1 (n=50) consisted of HBsAg(+) renal transplant recipients (RTR) whose donors were HBsAg(-). In Group 2 (n=5), RTR and donors were both HBsAg(+). Lymphocyte cross matches, number of mismatches, donor types, renal replacement treatment modalities, drugs of induction treatment, and preoperative hepatitis B virus DNA titers of the groups were similar. In Group 1, 42 patients were taking lamivudine, 3 patients were taking entecavir, and 5 patients were taking tenofovir. All of the patients in Group 2 were taking lamivudine. Patient and graft survival rates, graft functions, acute hepatitis rates, acute rejection rates, and other clinical outcomes of the groups were compared. ResultsDemographic data of the groups were similar. Acute rejection rates (P=0.458), graft survival rates (P=0.515), and patient survival rates (P=0.803) were also similar. No significant difference was found between the groups in terms of acute hepatitis rate (P=0.511), glomerular filtration rate (calculated by Modification of Diet in Renal Disease formula) in the last follow-up (P=0.988), alanine aminotransferase levels (P=0.069), or delayed graft function rate (P=0.973). Rates of chronic allograft dysfunction and new onset diabetes mellitus after transplantation were similar. ConclusionOur study revealed that, RTx from HBsAg(+) donors to HBsAg(+) recipients is safe with antiviral treatment.en_US
dc.identifier.doi10.1111/tid.12482
dc.identifier.endpage62en_US
dc.identifier.issn1398-2273
dc.identifier.issn1399-3062
dc.identifier.issue1en_US
dc.identifier.pmid26565663
dc.identifier.scopus2-s2.0-84958677059
dc.identifier.scopusqualityQ2
dc.identifier.startpage55en_US
dc.identifier.urihttps://doi.org/10.1111/tid.12482
dc.identifier.urihttps://hdl.handle.net/11468/17746
dc.identifier.volume18en_US
dc.identifier.wosWOS:000370449800007
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofTransplant Infectious Disease
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRenal Transplantationen_US
dc.subjectHepatitis B Virusen_US
dc.subjectAcute Hepatitisen_US
dc.subjectLamivudineen_US
dc.subjectLiver Failureen_US
dc.titleEffects of hepatitis B surface antigen (HBsAg) positivity of donors in HBsAg(+) renal transplant recipients: comparison of outcomes with HBsAg(+) and HBsAg(-) donorsen_US
dc.titleEffects of hepatitis B surface antigen (HBsAg) positivity of donors in HBsAg(+) renal transplant recipients: comparison of outcomes with HBsAg(+) and HBsAg(-) donors
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu